Alleviating doxorubicin-induced reproductive toxicity: protective and androgenic effects of drone larvae on sperm morphology and hormonal balance.

Abstract

Male infertility and compromised sperm quality are common side effects of Doxorubicin (DOX), a widely used chemotherapy drug. Its detrimental impact on male reproductive cells underscores the urgent need for effective protective measures. Lyophilized drone larvae (DL) from apitherapy have emerged as a potential solution due to their reported protective properties. By exploring DL's therapeutic potential, this research seeks to address the pressing need for strategies to protect male reproductive health during cancer treatment. The study aims to evaluate the protective effects of lyophilized DL from apitherapy against DOX-induced testicular damage in adult Sprague-Dawley rats. DOX negatively impacts male reproductive cells, leading to infertility and compromised sperm quality. Investigating DL's protective properties is crucial for understanding its therapeutic potential in mitigating such adverse effects. Forty rats were divided into four groups: control, DOX-treated, DL-treated, and DOX + DL-treated. Histopathological assessments, biochemical analyses (TAS, TOS, CAT, SOD, GPX), inflammatory marker measurements (TNF-α, IL-1β, IL-6), and comet assays for DNA damage were conducted on testicular tissue and blood samples. DOX induced histopathological alterations in the testis and epididymis, which DL mitigated. DL increased TAS levels, counteracted DOX-induced decreases in glutathione peroxidase (GPx), total protein, albumin, and increases in total cholesterol. DL also mitigated the rise in Follicle-Stimulating Hormone (FSH) levels caused by DOX, while increasing testosterone levels and lowering Luteinizing Hormone (LH) levels. Inflammatory markers remained unaffected. Tail moment measurements indicated a protective effect against DOX-induced DNA damage in erythrocytes with DL. DL protected sperm morphology, count, and Johnsen's score from DOX-induced reductions, suggesting its potential in mitigating cancer treatment side effects on male reproductive health. The findings suggest that DL, as an apitherapy product, holds significant promise in mitigating DOX's adverse effects on male reproductive systems. However, further investigations into its mechanisms and clinical applications in cancer therapy are warranted, emphasizing the need for continued research to fully understand DL's therapeutic benefits.